The diagnosis of cirrhosis, especially in the advanced/decompensated stages, is made using simple and inexpensive clinico-radiologicpathological techniques 1 . Qin et al. 2 , whose paper has replicated prior studies [3] [4] [5] , reported a relatively novel profile to diagnose cirrhosis using complex stool metagenomics despite having a majority (65% discovery and 76% validation cohorts) decompensated cirrhotic population. We have found that the decompensated cirrhosis cohort, which does not require these complicated diagnostic strategies, was responsible for a significant proportion of these microbiota changes on further analysis of their metagenomics data and using a new cohort of 360 subjects. Therefore, given several confounders and the ease of decompensated cirrhosis diagnosis using current techniques, a careful re-interpretation of newer microbiota-based diagnostic strategies that do not a priori differentiate between early (compensated) and decompensated cirrhosis and treat all people with cirrhosis as one uniform population should be performed. There is a Reply to this Brief Communication Arising by Qin, N. et al. Nature 525, http:// dx.doi.org/10.1038/nature14852 (2015).
A major confounder in people with cirrhosis are standard of care therapies such as lactulose, rifaximin, antibiotics and acid-suppressants that can affect the gut milieu 1, 6 . These alone could explain a large portion of the metagenomics changes and have not been accounted for 5, [7] [8] [9] . These medications, especially proton pump inhibitors, could also be a major reason why oral origin bacteria are found in the intestine, as has been shown in prospective cirrhotic and non-cirrhotic studies 10, 11 . We hypothesized that there was a significant difference in compensated versus decompensated cirrhotic microbiota in Qin et al. 2 , which needs to be accounted for in the interpretation. Using 66 enriched/ depleted metagenomic sequences (MGS) provided by S. D. Ehrlich, we performed linear discriminant analysis (LDA) effect size (LEfSe) 12 after classifying them into healthy, compensated and decompensated subjects. LEFSe uses a factorial Kruskal-Wallis and LDA test to detect features with significant differential abundance. We found that even in the selected data set the authors provided, 17 of 66 MGS were different between compensated and decompensated groups (10 MGS overexpressed and 7 MGS underexpressed, Fig. 1a ). These included several oral origin species (Streptococcus oralis and several Veillonella spp.), which were the primary study results. We then enrolled 360 agematched subjects (45 healthy individuals (age 54 6 3 years, no chronic diseases), 171 compensated (age 54 6 4 years, median Child-Pugh score 6) and 141 decompensated cirrhotic patients (age 55 6 2 years, median Child-Pugh score 9)) for stool multi-tagged pyrosequencing (MTPS) 13 . Using Kruskal-Wallis analysis of relative microbial family abundance .1%, we found that compensated and decompensated patients were significantly different (Fig. 1b) . Proteobacteria levels, specifically Enterobacteriaceae, were significantly higher in decompensated cirrhotic patients. This pattern is also seen in other recent MTPS studies 4, 14 . Although MGS and MTPS are not completely comparable, it is interesting that both resulted in similar conclusions. Therefore, there are significant microbiota differences between compensated and decompensated patients that need to be separated in cirrhosis microbial studies.
In addition, in Qin et al. 2 the calculation of the model for end-stage liver disease (MELD) score in Supplementary Table 1 is inaccurate, casting doubt on figure 2. The authors compared diabetes patients with cirrhotic patients to inform their cirrhosis-associated profile. However, diabetes is prevalent and is associated with a poor prognosis in cirrhosis 15 . Therefore these results are not generalizable to patients with cirrhosis and diabetes.
The present need is not for complicated profiles that are unlikely to supplant currently available simple diagnostic strategies, but rather for improving prognostication. This is because gut microbiota are associated with several cirrhosis-related pre-terminal events such as hepatic encephalopathy and infections 1 . A prior study has shown that altered stool microbiota can predict poor outcomes, but further work is required 8 . . b, In the new data set using MTPS, boxplots showing interquartile range of median abundance of statistically significant comparisons between controls (orange), compensated cirrhosis (green) and decompensated cirrhosis (blue) using multiple corrections-adjusted Kruskal-Wallis tests at the family level. The line in the centre shows median.
Therefore, the careful separation of the two groups within cirrhosis, which have different diagnostic criteria and prognoses, and the control of confounders owing to drugs mentioned above, are important for the correct interpretation of these results and to avoid epiphenomena. In the accompanying Comment 1 , a concern expressed by Bajaj et al. is that diagnostics of liver cirrhosis by microbiome analysis that we report 2 may be mainly due to the microbiome alterations in decompensated patients (DP). To address it we tested how accurately compensated patients (CP) can be diagnosed by microbiome analysis. Two slightly different criteria of identifying these were used, based on absence of ascites and hepatic encephalopathy (n 5 54) and absence of ascites only (n 5 57).
First, we constructed a discriminator of patients (P, n 5 98) and healthy controls (H, n 5 83) in the discovery cohort, disregarding the patient status (CP or DP). For that we used as input the presence and abundance of 66 metagenomic species (MGS) differentially represented in the two groups 2 and as output area under curve (AUC) of a receiver operator characteristic (ROC) analysis, essentially as described previously 3, 4 . The optimal discriminator required 7 MGS only and yielded an AUC of 0.95 for the discovery cohort and of 0.94 for the validation cohort (P n 5 25; H n 5 31), values somewhat higher than those observed for the discriminator based on 15 biomarkers 2 . The discriminator stratified the CP (n 5 54 or n 5 57) from H (n 5 114) as accurately as the DP (n 5 69 or n 5 66), with an AUC of 0.95 for all. This shows that the gut microbiome alterations in the two types of patients have highly similar features. These features are not greatly affected by medication, another concern expressed by Bajaj et al.
1
, as the discriminator stratified with a comparable efficiency H (n 5 114) from P that were taking antiviral medication (n 5 52) or not (n 5 71) with an AUC of 0.95 for both; taking b-blockers (n 5 11) or not (n 5 112), with an AUC of 0.95 and 0.96, respectively; or taking PPI (n 5 70) or not (n 5 53), with an AUC of 0.96 and 0.93, respectively. We suggest that the inability to construct an efficient discriminator of H and CP by Bajaj et al.
1 may be due to an inadequate resolution provided by the broadly used gene encoding the 16S ribosomal RNA, which remains generally at the genus level rather than the species one achieved by quantitative metagenomics we deploy [2] [3] [4] . Notwithstanding the similarity of the gut microbiome alterations in CP and DP, there are also differences between the two groups, as suggested by the association of the disease severity scores and the load of the liver cirrhosis-enriched species 2 . Bajaj et al.
1 rightly point out an inaccuracy of the calculation of the model for end-stage liver disease (MELD) score in our report 2 , which refers to previous literature; however, the correction had a modest effect, the statistical significance between the scores of patients with the lowest and the highest LC quartile load being P , 2 3 10 25 rather than the reported P , 1 3 10
25
. To further explore the microbiome alterations in CP and DP we searched for the MGS having a significantly different abundance in the two groups, following the approach used for identifying 66 species enriched in C or P groups 2 . Some 30 such MGS were found in the discovery cohort (CP n 5 45; DP n 5 54), but only 13 were not present in the set of 66. All 79 species were used to construct the best discriminator for the discovery cohort. It was based on 14 MGS and stratified the CP and DP of the discovery cohort with an AUC of 0.87 and those of the validation cohort (CP n 5 9; DP n 5 16) with an AUC of 0.84.
This analysis confirms our finding that the alterations of the gut microbiome are associated with the severity of the disease. However, it provides no evidence for a saltatory alteration to a different composition upon decompensation, which could confound microbiome analysis, as suggested by Bajaj et al.
1 ; a gradual alteration with the severity would lead to the same result.
Diabetes has been excluded in the patient enrolment in our study 2 . Furthermore, invasion of the gut by oral species was not observed in the previous studies of the type-2 diabetes, notwithstanding the use of quantitative metagenomics, which would have easily revealed them were they present 5, 6 . Alterations of the gut microbiome owing to liver cirrhosis are therefore unlikely to be confounded by diabetes and the diagnostics of the two pathologies by the gut microbiome analysis remains a real possibility. Short-term nutritional changes, such as hospital diet, generally have only a modest effect on gut microbiota; long term dietary patterns, which affect it more 7, 8 , are not very significantly different for the cirrhosis patients and healthy controls in the Chinese population from which the participants enrolled in our study were drawn 2 . In conclusion, while we adhere to the call of Bajaj et al.
1 for caution regarding potential confounders in microbiome analysis, we strongly disagree with their suggestion that the alterations we report are "epiphenomena" rather than actual differences of gut microbial communities associated with liver cirrhosis. We suggest that microbiome analysis might supplant current inadequate clinical diagnostic parameters and/or invasive procedures such as liver biopsy for detecting compensated cirrhosis. 
